Email Alert | RSS

北京大学学报（医学版） ›› 2022, Vol. 54 ›› Issue (6): 1224-1228. doi: 10.19723/j.issn.1671-167X.2022.06.028

• 短篇论著 • 上一篇    下一篇

以雷诺现象为首发表现的系统性硬化症临床特征及其相关因素

罗靓1,2,蔡青猛1,刘香君1,贠泽霖1,李春1,张晓盈1,*()   

  1. 1 北京大学人民医院风湿免疫科，北京 100044
    2 重庆市渝北区人民医院中医科，重庆 401120
  • 收稿日期:2022-08-22 出版日期:2022-12-18 发布日期:2022-12-19
  • 通讯作者: 张晓盈 E-mail:zhangxiaoying@pkuph.edu.cn
  • 基金资助:
    中华国际医学交流基金会基金(Z-2018-40-2101);北京大学人民医院研究与发展基金(RDE 2021-18)

靓 罗1,2,青猛 蔡1,香君 刘1,泽霖 贠1,春 李1,晓盈 张1,*()   

  • Received:2022-08-22 Online:2022-12-18 Published:2022-12-19
  • Contact: 晓盈 张 E-mail:zhangxiaoying@pkuph.edu.cn
  • Supported by:
    China International Medical Foundation(Z-2018-40-2101);Peking University People's Hospital Scientific Research Development Funds(RDE 2021-18)

RICH HTML

   

PDF (PC)

关键词: 系统性硬化症, 雷诺现象, 危险因素

中图分类号: 

  • R593.25

表1

两组患者一般资料比较"

Variables RP onset group (n=196) NRP onset group (n=105) Z/t/χ2 P
Female, n (%) 169 (86.2) 88 (83.8) 0.319 0.572
Age at onset/years, $\bar x \pm s$ 42.4±15.5 46.1±14.6 -2.064 0.040
Duration/months, M (P25, P75) 78.0 (29.0, 176.5) 52.0 (21.5, 124.5) -1.792 0.073
Smoking, n (%) 29 (14.8) 23 (21.9) 2.418 0.120
SLE, n (%) 15 (7.7) 4 (3.8) 1.708 0.191
RA, n (%) 16 (8.2) 6 (5.7) 0.605 0.437
Inflammatory myopathy, n (%) 6 (3.1) 3 (2.9) 0.000 >0.999
Hypertension, n (%) 44 (22.4) 26 (24.8) 0.205 0.651
Diabetes, n (%) 8 (4.1) 10 (9.5) 3.602 0.058
Hyperlipidemia, n (%) 16 (8.2) 9 (8.6) 0.015 0.903

表2

两组患者临床表现比较[n(%)]"

Variables RP onset group (n=196) NRP onset group (n=105) χ2 P
Skin manifestations
  Skin hardening/thickening 174 (88.8) 99 (94.3) 2.461 0.117
  Loss of digital pad tissue 26 (13.3) 5 (4.8) 5.351 0.021
Bones/muscles manifestations
  Muscle pain 34 (17.3) 20 (19.0) 0.134 0.714
  Joint swelling 59 (30.1) 34 (32.4) 0.166 0.683
  Arthralgia 93 (47.4) 57 (54.3) 1.278 0.258
Vascular manifestations
vFingertip ulcers 49 (25.0) 15 (14.3) 4.688 0.030
  Digital gangrene 7 (3.6) 0 N/A 0.101
Cardiopulmonary system manifestations
  Palpitations 22 (11.2) 14 (13.3) 0.289 0.591
  ILD 92 (46.9) 32 (30.5) 7.649 0.006
  PAH 39 (19.9) 10 (9.5) 5.399 0.020
Digestive involvement
  Reflux/Heartburn 87 (44.4) 40 (38.1) 1.110 0.292
  Stomach fullness 26 (13.3) 6 (5.7) 4.103 0.043
  Intermittent abdominal pain 13 (6.6) 3 (2.9) 1.936 0.164
Renal involvement
  Proteinuria 14 (7.1) 7 (6.7) 0.024 0.877
  Microscopic hematuria 4 (2.0) 3 (2.9) 0.002 0.963
  Renal crisis 3 (1.5) 1 (1.0) 0.000 >0.999

表3

两组实验室指标比较"

Variables RP onset group (n=196) NRP onset group (n=105) Z/t/χ2 P
TC/(mmol/L), M (P25, P75) 4.35 (3.55, 5.13) 4.40 (3.70, 5.13) -1.016 0.310
TG/(mmol/L), M (P25, P75) 1.55 (1.07, 2.15) 1.44 (1.04, 2.19) -0.349 0.727
HDL-C/(mmol/L), $\bar x \pm s$ 1.13 ± 0.36 1.13 ± 0.31 -0.062 0.951
LDL-C/(mmol/L), $\bar x \pm s$ 2.54 ± 0.80 2.74 ± 0.75 -2.205 0.028
ALT/(U/L), M (P25, P75) 16.0 (11.0, 23.0) 15.0 (11.0, 21.5) -0.764 0.445
AST/(U/L), M (P25, P75) 22.0 (17.0, 26.0) 20.0 (15.0, 25.0) -1.180 0.238
Scr/(μmol/L), M (P25, P75) 61.5 (49.0, 69.8) 59.0 (53.0, 70.0) -0.038 0.970
ESR/(mm/h), M (P25, P75) 16.0 (8.0, 25.8) 15.0 (8.0, 23.0) -1.141 0.254
CRP/(mg/L), M (P25, P75) 3.1 (1.2, 7.3) 3.2 (1.5, 7.3) -0.275 0.784
ANA positive, n (%) 190 (96.9) 97 (92.4) 2.257 0.133
Anti-Scl-70 positive, n (%) 65 (33.2) 23 (21.9) 4.189 0.041
Anti-RNP positive, n (%) 30 (15.3) 16 (15.2) 0.000 0.988
Low C3, n (%) 45 (23.0) 22 (21.0) 0.159 0.690
Low C4, n (%) 41 (20.9) 23 (21.9) 0.040 0.842
IgA elevated, n (%) 54 (27.6) 22 (21.0) 1.577 0.209
IgG elevated, n (%) 38 (19.4) 26 (24.8) 1.180 0.277
IgM elevated, n (%) 38 (19.4) 16 (15.2) 0.800 0.371

表4

RP为首发表现SSc相关因素的二元Logistic回归分析结果"

VariablesUnivariate Multivariate
B Wald P OR (95%CI) B Wald P OR (95%CI)
Age at onset -0.016 4.024 0.045 0.984 (0.968-1.000)
Diabetes -0.906 3.406 0.065 0.040 (0.154-1.158)
Loss of digital pad tissue 1.118 4.915 0.027 3.059 (1.138-8.219) 1.290 6.103 0.013 3.634 (1.306-10.118)
Fingertip ulcers 0.693 4.576 0.032 2.000 (1.060-3.774)
ILD 0.702 7.534 0.006 2.018 (1.222-3.332) 0.679 6.688 0.010 1.972 (1.179-3.299)
PAH 0.859 5.172 0.023 2.360 (1.126-4.946)
Stomach fullness 0.926 3.875 0.049 2.524 (1.004-6.343)
Anti-Scl-70 positive 0.570 4.135 0.042 1.769 (1.021-3.066) 0.596 4.211 0.040 1.814 (1.027-3.205)
Low LDL-C -0.330 4.548 0.033 0.719 (0.531-0.974) -0.403 5.979 0.014 0.668 (0.484-0.923)
1 Wigley FM , Flavahan NA . Raynaud's phenomenon[J]. N Engl J Med, 2016, 375 (6): 556- 565.
doi: 10.1056/NEJMra1507638
2 Pauling JD , Hughes M , Pope JE . Raynaud's phenomenon: An update on diagnosis, classification and management[J]. Clin Rheumatol, 2019, 38 (12): 3317- 3330.
doi: 10.1007/s10067-019-04745-5
3 刘晶, 史群, 徐东, 等. 雷诺现象为首发表现的自身免疫性疾病疾病谱及临床特点[J]. 中华临床免疫和变态反应杂志, 2013, 7 (4): 346- 350.
4 Schneeberger D , Tyndall A , Kay J , et al. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: A multicentre study in the prospective EULAR scleroderma trials and research (EUSTAR) database[J]. Rheumatology (Oxford), 2013, 52 (3): 560- 567.
doi: 10.1093/rheumatology/kes315
5 Walker UA , Tyndall A , Czirják L , et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database[J]. Ann Rheum Dis, 2007, 66 (6): 754- 763.
doi: 10.1136/ard.2006.062901
6 Matucci-Cerinic M , Kahaleh B , Wigley FM . Review: Evidence that systemic sclerosis is a vascular disease[J]. Arthritis Rheum, 2013, 65 (8): 1953- 1962.
doi: 10.1002/art.37988
7 Bairkdar M , Rossides M , Westerlind H , et al. Incidence and prevalence of systemic sclerosis globally: A comprehensive syste-matic review and meta-analysis[J]. Rheumatology (Oxford), 2021, 60 (7): 3121- 3133.
doi: 10.1093/rheumatology/keab190
8 Galetti I , Nunzio SD , Brogelli L , et al. How do systemic sclerosis manifestations influence patients' lives? Results from a survey on patients and caregivers[J]. Curr Med Res Opin, 2021, 37 (Suppl 2): 5- 15.
9 Elhai M , Meune C , Boubaya M , et al. Mapping and predicting mortality from systemic sclerosis[J]. Ann Rheum Dis, 2017, 76 (11): 1897- 1905.
doi: 10.1136/annrheumdis-2017-211448
10 Preliminary criteria for the classification of systemic sclerosis (scleroderma) . Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum, 1980, 23 (5): 581- 590.
doi: 10.1002/art.1780230510
11 van den Hoogen F , Khanna D , Fransen J , et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative[J]. Ann Rheum Dis, 2013, 72 (11): 1747- 1755.
doi: 10.1136/annrheumdis-2013-204424
12 Bussone G , Mouthon L . Interstitial lung disease in systemic sclerosis[J]. Autoimmun Rev, 2011, 10 (5): 248- 255.
doi: 10.1016/j.autrev.2010.09.012
13 Simonneau G , Robbins IM , Beghetti M , et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardiol, 2009, 54 (Suppl 1): S43- S54.
14 Bruni C , De Luca G , Lazzaroni MG , et al. Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review[J]. Eur J Intern Med, 2020, 78, 17- 25.
doi: 10.1016/j.ejim.2020.05.042
15 Denton CP , Khanna D . Systemic sclerosis[J]. Lancet, 2017, 390 (10103): 1685- 1699.
doi: 10.1016/S0140-6736(17)30933-9
16 Maciejewska M , Sikora M , Maciejewski C , et al. Raynaud's phenomenon with focus on systemic sclerosis[J]. J Clin Med, 2022, 11 (9): 2490.
doi: 10.3390/jcm11092490
17 Rubio-Rivas M , Corbella X , Pestaóa-Fernández M , et al. First clinical symptom as a prognostic factor in systemic sclerosis: Results of a retrospective nationwide cohort study[J]. Clin Rheumatol, 2018, 37 (4): 999- 1009.
doi: 10.1007/s10067-017-3936-7
18 Launay D , Sitbon O , Hachulla E , et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era[J]. Ann Rheum Dis, 2013, 72 (12): 1940- 1946.
doi: 10.1136/annrheumdis-2012-202489
19 Nihtyanova SI , Schreiber BE , Ong VH , et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis[J]. Arthritis Rheumatol, 2014, 66 (6): 1625- 1635.
doi: 10.1002/art.38390
20 Wise RA , Wigley F , Newball HH , et al. The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon[J]. Chest, 1982, 81 (6): 695- 698.
doi: 10.1378/chest.81.6.695
21 Wangkaew S , Pota P , Prasertwittayakij N , et al. Incidence, predictors, and survival of pulmonary hypertension determined by echocardiography in Thai patients with early systemic sclerosis (SSc): Inception cohort study[J]. Clin Rheumatol, 2021, 40 (3): 973- 980.
doi: 10.1007/s10067-020-05296-w
22 Perelas A , Silver RM , Arrossi AV , et al. Systemic sclerosis-associated interstitial lung disease[J]. Lancet Respir Med, 2020, 8 (3): 304- 320.
doi: 10.1016/S2213-2600(19)30480-1
23 Khanna D , Nagaraja V , Tseng CH , et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials[J]. Arthritis Res Ther, 2015, 17, 372.
doi: 10.1186/s13075-015-0872-2
24 Rubio-Rivas M , Royo C , Simeón CP , et al. Mortality and survival in systemic sclerosis: Systematic review and meta-analysis[J]. Semin Arthritis Rheum, 2014, 44 (2): 208- 219.
doi: 10.1016/j.semarthrit.2014.05.010
25 Meunier P , Dequidt L , Barnetche T , et al. Increased risk of mortality in systemic sclerosis-associated digital ulcers: A systematic review and meta-analysis[J]. J Eur Acad Dermatol Venereol, 2019, 33 (2): 405- 409.
doi: 10.1111/jdv.15114
26 Bering J , Griffing WL , Crowell M , et al. Progression of gastrointestinal symptoms over time in patients with systemic sclerosis[J]. Rheumatol Int, 2021, 41 (7): 1281- 1287.
doi: 10.1007/s00296-021-04806-6
27 Steelandt A , Benmostefa N , Avouac J , et al. Ethnic influence on the phenotype of French patients with systemic sclerosis[J]. Joint Bone Spine, 2021, 88 (2): 105081.
doi: 10.1016/j.jbspin.2020.09.013
28 Kowal-Bielecka O , Fransen J , Avouac J , et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017, 76 (8): 1327- 1339.
doi: 10.1136/annrheumdis-2016-209909
[1] 魏慧, 张警丰, 姚中强, 赵金霞. 类风湿关节炎合并慢性病贫血患者的临床特征及相关因素[J]. 北京大学学报（医学版）, 2026, 58(2): 307-312.
[2] 赵杰, 付春, 赵秀娟, 薛海岩, 李纾, 王振洲, 朱凤雪. 胸部创伤患者在重症监护病房内发生呼吸机相关性肺炎的危险因素[J]. 北京大学学报（医学版）, 2026, 58(2): 351-358.
[3] 郭芷均, 俎明, 马超, 张贺军, 张静, 丁士刚. 同时性多发早期胃癌漏诊病灶的临床病理特征[J]. 北京大学学报（医学版）, 2026, 58(2): 410-415.
[4] 梁景原, 张霞, 姚海红. 误诊为系统性硬化症的POEMS综合征1例[J]. 北京大学学报（医学版）, 2025, 57(6): 1184-1187.
[5] 李博闻, 张强, 孙益鑫. 儿童及青年漏斗胸患者Nuss术后发生脊柱侧弯的风险预测模型建立及验证[J]. 北京大学学报（医学版）, 2025, 57(5): 941-946.
[6] 杨小勇, 张帆, 马潞林, 刘承. 前列腺导管腺癌临床特征及腺外侵犯的影响因素[J]. 北京大学学报（医学版）, 2025, 57(5): 956-960.
[7] 刘伟, 郭稳, 过哲, 李春艳, 李云龙, 刘思奇, 张亮, 宋慧. 痛风患者放射学阴性骨侵蚀的相关危险因素[J]. 北京大学学报（医学版）, 2025, 57(4): 735-739.
[8] 陆梦溪, 刘秋萍, 周恬静, 刘晓非, 孙烨祥, 沈鹏, 林鸿波, 唐迅, 高培. 基于社区人群队列的甘油三酯-葡萄糖指数与心血管病发病和死亡的关联[J]. 北京大学学报（医学版）, 2025, 57(3): 430-435.
[9] 杨龙傲, 金旭, 黄文初, 何丽华, 陈娟. 视屏作业人员视疲劳及干眼的流行病学调查[J]. 北京大学学报（医学版）, 2025, 57(3): 554-561.
[10] 郭华秋, 王哲, 杨雪, 白洁. 口腔急诊出血患者的临床特征与危险因素[J]. 北京大学学报（医学版）, 2025, 57(1): 142-147.
[11] 邓敏婷, 王楠, 夏斌, 赵玉鸣, 朱俊霞. 儿童及青少年挫入恒前牙自行再萌出的相关影响因素[J]. 北京大学学报（医学版）, 2025, 57(1): 148-153.
[12] 李钰锴, 王红彦, 罗靓, 李云, 李春. 抗磷脂抗体在白塞病合并血栓中的临床意义[J]. 北京大学学报（医学版）, 2024, 56(6): 1036-1040.
[13] 潘苇, 李云, 罗俊佳, 李春, 叶华, 李雪, 贾园. 系统性硬化症患者新型冠状病毒感染特点及疫苗接种效果：一项单中心队列研究[J]. 北京大学学报（医学版）, 2024, 56(6): 1041-1046.
[14] 田杨, 韩永正, 李娇, 王明亚, 曲音音, 房景超, 金辉, 李民, 王军, 徐懋, 王圣林, 郭向阳. 颈椎前路手术后硬膜外血肿的发生率和危险因素[J]. 北京大学学报（医学版）, 2024, 56(6): 1058-1064.
[15] 王明瑞, 赖金惠, 姬家祥, 唐鑫伟, 胡浩浦, 王起, 许克新, 徐涛, 胡浩. 使用中文版威斯康星结石生活质量问卷预测肾结石患者生活质量降低的危险因素[J]. 北京大学学报（医学版）, 2024, 56(6): 1069-1074.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部